SmgGDS-558 regulates the cell cycle in pancreatic, non-small cell lung, and breast cancers

Cell Cycle

Volumn 13, Issue 6, 2014, Pages 941-952

  Schuld, Nathan J ^a   Hauser, Andrew D ^a   Gastonguay, Adam J ^a   Wilson, Jessica M ^a   Lorimer, Ellen L ^a   Williams, Carol L ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Breast cancer; Cell cycle; GTPase; Lung cancer; Mouse tumorigenesis; Pancreatic cancer; Proliferation; Rap1GDS1; RNAi; SmgGDS

Indexed keywords

CELL CYCLE PROTEIN; CYCLIN D1; GUANOSINE TRIPHOSPHATASE; PROTEIN P21; PROTEIN P27; SMGGDS 558; SMGGDS 607; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CARCINOGENESIS; CELL COUNT; CELL CYCLE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; G2 PHASE CELL CYCLE CHECKPOINT; IMMUNOBLOTTING; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PANCREAS CANCER; PROTEIN DEPLETION; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

BREAST CANCER; CELL CYCLE; GTPASE; LUNG CANCER; MOUSE TUMORIGENESIS; PANCREATIC CANCER; PROLIFERATION; RAP1GDS1; RNAI; SMGGDS;

ANIMALS; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; FEMALE; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HETEROGRAFTS; HUMANS; LUNG NEOPLASMS; MICE; MICE, SCID; PANCREATIC NEOPLASMS; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTEIN ISOFORMS; RHO GTP-BINDING PROTEINS;

EID: 84897979722     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.27804     Document Type: Article

References (64)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11-30; PMID:23335087; http://dx.doi.org/10.3322/caac.21166
2. Garcea G, Neal CP, Pattenden CJ, Steward WP, Berry DP. Molecular prognostic markers in pancreatic cancer: a systematic review. Eur J Cancer 2005; 41:2213-36; PMID:16146690; http://dx.doi.org/10.1016/j.ejca.2005.04.044
3. Kusama T, Mukai M, Iwasaki T, Tatsuta M, Matsumoto Y, Akedo H, Nakamura H. Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors. Cancer Res 2001; 61:4885-91; PMID:11406567
4. Taniuchi K, Nakagawa H, Hosokawa M, Nakamura T, Eguchi H, Ohigashi H, Ishikawa O, Katagiri T, Nakamura Y. Overexpressed P-cadherin/CDH3 promotes motility of pancreatic cancer cells by interacting with p120ctn and activating rho-family GTPases. Cancer Res 2005; 65:3092-9; PMID:15833838
5. Liu Y, Wang Y, Zhang Y, Miao Y, Zhao Y, Zhang PX, Jiang GY, Zhang JY, Han Y, Lin XY, et al. Abnormal expression of p120-catenin, E-cadherin, and small GTPases is significantly associated with malignant phenotype of human lung cancer. Lung Cancer 2009; 63:375-82; PMID:19162367; http://dx.doi.org/10.1016/j. lungcan.2008.12.012
6. Tang Y, Olufemi L, Wang MT, Nie D. Role of Rho GTPases in breast cancer. Front Biosci 2008; 13:759-76; PMID:17981586; http://dx.doi.org/10.2741/2718
7. Clark GJ, Der CJ. Aberrant function of the Ras signal transduction pathway in human breast cancer. Breast Cancer Res Treat 1995; 35:133-44; PMID:7612899; http://dx.doi.org/10.1007/BF00694753
8. Shima F, Yoshikawa Y, Ye M, Araki M, Matsumoto S, Liao J, Hu L, Sugimoto T, Ijiri Y, Takeda A, et al. In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras-effector interaction. Proc Natl Acad Sci USA 2013; 110:8182-7; PMID:23630290; http://dx.doi.org/10.1073/pnas.1217730110
9. Nussinov R, Tsai CJ, Mattos C. 'Pathway drug cocktail': targeting Ras signaling based on structural pathways. Trends Mol Med 2013; 19:695-704; PMID:23953481; http://dx.doi.org/10.1016/j.molmed.2013.07.009
10. Patel M, Côté JF. Ras GTPases' interaction with effector domains: Breaking the families' barrier. Commun Integr Biol 2013; 6:e24298; PMID:23986800; http://dx.doi.org/10.4161/cib.24298
11. Cherfils J, Zeghouf M. Regulation of small GTPases by GEFs, GAPs, and GDIs. Physiol Rev 2013; 93:269-309; PMID:23303910; http://dx.doi.org/10.1152/ physrev.00003.2012
12. Hayes TK, Der CJ. Mutant and wild-type Ras: co-conspirators in cancer. Cancer Discov 2013; 3:24-6; PMID:23319767; http://dx.doi.org/10.1158/2159-8290. CD-12-0521
13. Flemming A. Cancer: double-pronged approach to combat mutant KRAS. Nat Rev Drug Discov 2013; 12:188-9; PMID:23449300; http://dx.doi.org/10.1038/nrd3969
14. Wang Y, Kaiser CE, Frett B, Li HY. Targeting mutant KRAS for anticancer therapeutics: A review of novel small molecule modulators. J Med Chem 2013; 56:5219-30; PMID:23566315; http://dx.doi.org/10.1021/jm3017706
15. Williams CL. The polybasic region of Ras and Rho family small GTPases: a regulator of protein interactions and membrane association and a site of nuclear localization signal sequences. Cell Signal 2003; 15:1071-80; PMID:14575862; http://dx.doi.org/10.1016/S0898-6568(03)00098-6
16. Marakasova E, Akhmatova N, Amaya M, Eisenhaber B, Eisenhaber F, van Hoek M, et al. Prenylation: From bacteria to eukaryotes. Mol Biol 2013; 47:622-33; http://dx.doi.org/10.1134/S0026893313050130
17. Nguyen UT, Goodall A, Alexandrov K, Abankwa D. Isoprenoid modifications. In: Post-Translational Modifications in Health and Disease: Springer, 2011:1-37.
18. Berndt N, Hamilton AD, Sebti SM. Targeting protein prenylation for cancer therapy. Nat Rev Cancer 2011; 11:775-91; PMID:22020205; http://dx.doi.org/10. 1038/nrc3151
19. Piwnica-Worms D. Elucidating Mechanisms of Farnesyltransferase Inhibitor Action and Resistance in Breast Cancer by Bioluminescence Imaging 2010. DTIC Document.
20. Berg TJ, Gastonguay AJ, Lorimer EL, Kuhnmuench JR, Li R, Fields AP, Williams CL. Splice variants of SmgGDS control small GTPase prenylation and membrane localization. J Biol Chem 2010; 285:35255-66; PMID:20709748; http://dx.doi.org/10.1074/jbc.M110.129916
21. Ntantie E, Gonyo P, Lorimer EL, Hauser AD, Schuld N, McAllister D, Kalyanaraman B, Dwinell MB, Auchampach JA, Williams CL. An adenosine-mediated signaling pathway suppresses prenylation of the GTPase Rap1B and promotes cell scattering. Sci Signal 2013; 6:ra39; PMID:23716716; http://dx.doi.org/10.1126/ scisignal.2003374
22. Tew GW, Lorimer EL, Berg TJ, Zhi H, Li R, Williams CL. SmgGDS regulates cell proliferation, migration, and NFkappaB transcriptional activity in non-small cell lung carcinoma. J Biol Chem 2008; 283:963-76; PMID:17951244; http://dx.doi.org/10.1074/jbc.M707526200
23. Zhi H, Yang XJ, Kuhnmuench J, Berg T, Thill R, Yang H, See WA, Becker CG, Williams CL, Li R. SmgGDS is up-regulated in prostate carcinoma and promotes tumour phenotypes in prostate cancer cells. J Pathol 2009; 217:389-97; PMID:18973191; http://dx.doi.org/10.1002/path.2456
24. Hauser AD, Bergom C, Schuld NJ, Chen X, Lorimer EL, Huang J, et al. The SmgGDS splice variant SmgGDS-558 is a key promoter of tumor growth and RhoA signaling in breast cancer. Molecular cancer research. MCR 2013; In press; http://dx.doi.org/10.1158/1541-7786.MCR-13-0362.
25. Coleman ML, Marshall CJ, Olson MF. RAS and RHO GTPases in G1-phase cell-cycle regulation. Nat Rev Mol Cell Biol 2004; 5:355-66; PMID:15122349; http://dx.doi.org/10.1038/nrm1365
26. Villalonga P, Ridley AJ, Ridley AJ. Rho GTPases and cell cycle control. Growth Factors 2006; 24:159-64; PMID:17191359; http://dx.doi.org/10.1080/ 08977190600560651
27. Bosco EE, Mulloy JC, Zheng Y. Rac1 GTPase: a "Rac" of all trades. Cell Mol Life Sci 2009; 66:370-4; PMID:19151919; http://dx.doi.org/10. 1007/s00018-008-8552-x
28. Jung SM, Park SS, Kim WJ, Moon SK. Ras/ERK1 pathway regulation of p27KIP1-mediated G1-phase cell-cycle arrest in cordycepin-induced inhibition of the proliferation of vascular smooth muscle cells. Eur J Pharmacol 2012; 681:15-22; PMID:22366198; http://dx.doi.org/10.1016/j.ejphar.2012.02.003
29. Chang F, Steelman LS, Shelton JG, Lee JT, Navolanic PM, Blalock WL, Franklin R, McCubrey JA. Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway (Review). [review]. Int J Oncol 2003; 22:469-80; PMID:12579299
30. Gastonguay A, Berg T, Hauser AD, Schuld N, Lorimer E, Williams CL. The role of Rac1 in the regulation of NFκB activity, cell proliferation, and cell migration in non-small cell lung carcinoma. Cancer Biol Ther 2012; 13:647-56; PMID:22549160; http://dx.doi.org/10.4161/cbt.20082
31. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009; 9:153-66; PMID:19238148; http://dx.doi.org/10. 1038/nrc2602
32. Lu Z, Hunter T. Ubiquitylation and proteasomal degradation of the p21(Cip1), p27(Kip1) and p57(Kip2) CDK inhibitors. Cell Cycle 2010; 9:2342-52; PMID:20519948; http://dx.doi.org/10.4161/cc.9.12.11988
33. Shan J, Zhao W, Gu W. Suppression of cancer cell growth by promoting cyclin D1 degradation. Mol Cell 2009; 36:469-76; PMID:19917254; http://dx.doi.org/10.1016/j.molcel.2009.10.018
34. Welsh CF, Roovers K, Villanueva J, Liu Y, Schwartz MA, Assoian RK. Timing of cyclin D1 expression within G1 phase is controlled by Rho. Nat Cell Biol 2001; 3:950-7; PMID:11715015; http://dx.doi.org/10.1038/ncb1101-950
35. Halilovic E, She QB, Ye Q, Pagliarini R, Sellers WR, Solit DB, Rosen N. PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling. Cancer Res 2010; 70:6804-14; PMID:20699365; http://dx.doi.org/10.1158/0008-5472.CAN-10-0409
36. Stacey DW. Three observations that have changed our understanding of cyclin D1 and p27Kip1 in cell cycle control. Genes Cancer 2010; 1:1189-99; PMID:21779442; http://dx.doi.org/10.1177/1947601911403475
37. Cmielová J, Rezáčová M. p21Cip1/Waf1 protein and its function based on a subcellular localization [corrected]. J Cell Biochem 2011; 112:3502-6; PMID:21815189; http://dx.doi.org/10.1002/jcb.23296
38. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin ASNF Jr. NFkappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 1999; 19:5785-99; PMID:10409765
39. Ghantous A, Saikali M, Rau T, Gali-Muhtasib H, Schneider-Stock R, Darwiche N. Inhibition of tumor promotion by parthenolide: epigenetic modulation of p21. Cancer Prev Res (Phila) 2012; 5:1298-309; PMID:23037503; http://dx.doi.org/10.1158/1940-6207.CAPR-12-0230
40. Zupkovitz G, Grausenburger R, Brunmeir R, Senese S, Tischler J, Jurkin J, Rembold M, Meunier D, Egger G, Lagger S, et al. The cyclin-dependent kinase inhibitor p21 is a crucial target for histone deacetylase 1 as a regulator of cellular proliferation. Mol Cell Biol 2010; 30:1171-81; PMID:20028735; http://dx.doi.org/10.1128/MCB.01500-09
41. le Sage C, Nagel R, Egan DA, Schrier M, Mesman E, Mangiola A, Anile C, Maira G, Mercatelli N, Ciafrè SA, et al. Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J 2007; 26:3699-708; PMID:17627278; http://dx.doi.org/10.1038/sj.emboj.7601790
42. van den Heuvel S. Cell-cycle regulation. 2005; In: WormBook: The Online Review of C. elegans Biology [Internet]. Pasedena (CA): WormBook; 2005. Available from: http://www.ncbi.nlm.nih.gov/books/NBK19719/.
43. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993; 366:701-4; PMID:8259214; http://dx.doi.org/10.1038/366701a0
44. Yamamoto T, Kaibuchi K, Mizuno T, Hiroyoshi M, Shirataki H, Takai Y. Purification and characterization from bovine brain cytosol of proteins that regulate the GDP/GTP exchange reaction of smg p21s, ras p21-like GTP-binding proteins. J Biol Chem 1990; 265:16626-34; PMID:2118909
45. Kawamura S, Kaibuchi K, Hiroyoshi M, Hata Y, Takai Y. Stoichiometric interaction of smg p21 with its GDP/GTP exchange protein and its novel action to regulate the translocation of smg p21 between membrane and cytoplasm. Biochem Biophys Res Commun 1991; 174:1095-102; PMID:1900001; http://dx.doi.org/10.1016/ 0006-291X(91)91533-I
46. Mizuno T, Kaibuchi K, Yamamoto T, Kawamura M, Sakoda T, Fujioka H, Matsuura Y, Takai Y. A stimulatory GDP/GTP exchange protein for smg p21 is active on the post-translationally processed form of c-Ki-ras p21 and rhoA p21. Proc Natl Acad Sci USA 1991; 88:6442-6; PMID:1907371; http://dx.doi.org/10.1073/ pnas.88.15.6442
47. Hamel B, Monaghan-Benson E, Rojas RJ, Temple BRS, Marston DJ, Burridge K, Sondek J. SmgGDS is a guanine nucleotide exchange factor that specifically activates RhoA and RhoC. J Biol Chem 2011; 286:12141-8; PMID:21242305; http://dx.doi.org/10.1074/jbc.M110.191122
48. Gnad R, Kaina B, Fritz G. Rho GTPases are involved in the regulation of NFkappaB by genotoxic stress. Exp Cell Res 2001; 264:244-9; PMID:11262181; http://dx.doi.org/10.1006/excr.2001.5165
49. Kawanami D, Matoba K, Kanazawa Y, Ishizawa S, Yokota T, Utsunomiya K. Thrombin induces MCP-1 expression through Rho-kinase and subsequent p38MAPK/NFκB signaling pathway activation in vascular endothelial cells. Biochem Biophys Res Commun 2011; 411:798-803; PMID:21787749; http://dx.doi.org/10.1016/j.bbrc.2011.07.031
50. Bodemann BO, White MA. Ral GTPases and cancer: linchpin support of the tumorigenic platform. Nat Rev Cancer 2008; 8:133-40; PMID:18219307; http://dx.doi.org/10.1038/nrc2296
51. Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C, Strauss M. NFkappaB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol Cell Biol 1999; 19:2690-8; PMID:10082535
52. Rivard N, Boucher MJ, Asselin C, L'Allemain G. MAP kinase cascade is required for p27 down-regulation and S phase entry in fibroblasts and epithelial cells. Am J Physiol 1999; 277:C652-64; PMID:10516095
53. Laufs U, Marra D, Node K, Liao JK. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). J Biol Chem 1999; 274:21926-31; PMID:10419514; http://dx.doi.org/10.1074/jbc.274.31.21926
54. Yoshida Y, Kawata M, Miura Y, Musha T, Sasaki T, Kikuchi A, Takai Y. Microinjection of smg/rap1/Krev-1 p21 into Swiss 3T3 cells induces DNA synthesis and morphological changes. Mol Cell Biol 1992; 12:3407-14; PMID:1321333; http://dx.doi.org/10.1128/MCB.12.8.3407
55. Fujioka H, Kaibuchi K, Kishi K, Yamamoto T, Kawamura M, Sakoda T, Mizuno T, Takai Y. Transforming and c-fos promoter/enhancer-stimulating activities of a stimulatory GDP/GTP exchange protein for small GTP-binding proteins. J Biol Chem 1992; 267:926-30; PMID:1730682
56. Ramaswamy S, Nakamura N, Vazquez F, Batt DB, Perera S, Roberts TM, Sellers WR. Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci USA 1999; 96:2110-5; PMID:10051603; http://dx.doi.org/10.1073/ pnas.96.5.2110
57. Kandel ES, Skeen J, Majewski N, Di Cristofano A, Pandolfi PP, Feliciano CS, Gartel A, Hay N. Activation of Akt/protein kinase B overcomes a G(2)/m cell cycle checkpoint induced by DNA damage. Mol Cell Biol 2002; 22:7831-41; PMID:12391152; http://dx.doi.org/10.1128/MCB.22.22.7831-7841.2002
58. Winston JT, Coats SR, Wang YZ, Pledger WJ. Regulation of the cell cycle machinery by oncogenic ras. Oncogene 1996; 12:127-34; PMID:8552383
59. Aktas H, Cai H, Cooper GM. Ras links growth factor signaling to the cell cycle machinery via regulation of cyclin D1 and the Cdk inhibitor p27KIP1. Mol Cell Biol 1997; 17:3850-7; PMID:9199319
60. Muise-Helmericks RC, Grimes HL, Bellacosa A, Malstrom SE, Tsichlis PN, Rosen N. Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway. J Biol Chem 1998; 273:29864-72; PMID:9792703; http://dx.doi.org/10.1074/jbc.273.45.29864
61. Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 2001; 93:1062-74; PMID:11459867; http://dx.doi.org/10.1093/jnci/93. 14.1062
62. Winter-Vann AM, Casey PJ. Post-prenylation-processing enzymes as new targets in oncogenesis. Nat Rev Cancer 2005; 5:405-12; PMID:15864282; http://dx.doi.org/10.1038/nrc1612
63. Lanning CC, Daddona JL, Ruiz-Velasco R, Shafer SH, Williams CL. The Rac1 C-terminal polybasic region regulates the nuclear localization and protein degradation of Rac1. J Biol Chem 2004; 279:44197-210; PMID:15304504; http://dx.doi.org/10.1074/jbc.M404977200
64. Strassheim D, Shafer SH, Phelps SH, Williams CL. Small cell lung carcinoma exhibits greater phospholipase C-β1 expression and edelfosine resistance compared with non-small cell lung carcinoma. Cancer Res 2000; 60:2730-6; PMID:10825148